The Career Development Program (CDP) is an important component of this Leukemia SPORE application and the national SPORE program because it will assure a cadre of academic faculty who are translational scientists dedicated to discover and apply new approaches to understanding the etiology and epidemiology, prevention, diagnosis, treatment and cure of patients with leukemia. The goal of our CDP is to recruit, provide training and guidance {i.e. mentor and develop) and retain academic faculty level physicianscientists, clinician-investigators, and laboratory-based scientists who will dedicate their endeavors to leukemia translational research. Our focus will be primarily on recruitment of assistant professors. We will place special emphasis on recruiting qualified women and minorities. Indeed, all three of the candidates chosen for the first year positions are women and one is a minority. While any area of translational leukemia research will be considered, we will place special emphasis in our areas of strength which include human cancer genetics, animal models and preclinical and clinical experimental therapeutics. The goal will be to fund three positions at $100,000 each for one to three years. Applications will be solicited from all departments and centers at the Ohio State University Comprehensive Cancer Center (OSUCCC) and by the SPORE Administrative Core. They will be screened for eligibility and diversity by the CDP Leader before formal review begins to assure that the pool contains qualified women and minorities. Applications will be judged based on the potential of the candidate, the strength of the proposed research and the appropriateness of the mentors. Applications will be formally reviewed, scored and ranked by members of the SPORE CDP Steering Committee. Final selection will be made by the CDP Leader and SPORE Program Director in consultation with the SPORE Executive Committee. Each position will be funded for one year, with eligibility for a second and third year dependent upon satisfactory annual progress following evaluation by the awardee's co-mentors and the SPORE Executive Committee. The SPORE will provide $150,000 annual funding to the program;$150,000 annually in matching funds will be provided from the OSUCCC. Success of the program will be judged by the quality, of the science generated by the awardees, their success in obtaining external peer reviewed funding, their success in academic advancement and their retention in academia and leukemia translational research.

Public Health Relevance

The Career Development Program (CDP) is an important component of this Leukemia SPORE application and the national SPORE program because it will assure a cadre of academic faculty who are specially trained translational scientists and clinicians dedicated to discover and apply new approaches to understanding the etiology and epidemiology, prevention, diagnosis, treatment and cure of patients with leukemia. This program helps to assure the continuity of professionals focused on leukemia diseases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140158-05
Application #
8521139
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
5
Fiscal Year
2013
Total Cost
$141,367
Indirect Cost
$59,735
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Bhatnagar, Bhavana; Eisfeld, Ann-Kathrin; Nicolet, Deedra et al. (2016) Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. Br J Haematol 175:226-236
Gao, Keliang; Huang, Xiaomeng; Chiang, Chi-Ling et al. (2016) Induced Apoptosis Investigation in Wild-type and FLT3-ITD Acute Myeloid Leukemia Cells by Nanochannel Electroporation and Single-cell qRT-PCR. Mol Ther 24:956-64
Maharry, Sophia E; Walker, Christopher J; Liyanarachchi, Sandya et al. (2016) Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia. Cancer Discov 6:1036-51
Halley, Patrick D; Lucas, Christopher R; McWilliams, Emily M et al. (2016) Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model. Small 12:308-20
Mani, R; Yan, R; Mo, X et al. (2016) Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma. Vet Comp Oncol :
Bhatnagar, B; Blachly, J S; Kohlschmidt, J et al. (2016) Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3). Leukemia 30:1586-9
Rogers, K A; Ruppert, A S; Bingman, A et al. (2016) Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia 30:346-50
Goyama, S; Schibler, J; Gasilina, A et al. (2016) UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO. Leukemia 30:728-39
Kearney, Cathal J; Lucas, Christopher R; O'Brien, Fergal J et al. (2016) DNA Origami: Folded DNA-Nanodevices That Can Direct and Interpret Cell Behavior. Adv Mater 28:5509-24
Tarighat, S S; Santhanam, R; Frankhouser, D et al. (2016) The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia 30:789-99

Showing the most recent 10 out of 205 publications